On Apr. 6, 2020, Innovation Pharma announced that it is engaged in discussions with health care provider networks and hospitals both in the U.S. and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic.

Concurrently, laboratory testing of Brilacidin against SARS-CoV-2, the novel coronavirus responsible for COVID-19, will continue.